Idaho Urologic Institute, PA

Meridian, Idaho 83642

0 studies enrolling now · 11 studies all time

What they study most

Bladder Cancer, Breast Cancer, Gynecologic Cancer, Lymphoma, Metastatic Hormone-sensitive Prostate Cancer, Non-muscle Invasive Bladder Cancer (NMIBC), Nonneoplastic Condition, Prostate Cancer

Studies at this site

• Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer — Completed
• Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer — Completed
• Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer — Completed
• Diet in Altering Disease Progression in Patients With Prostate Cancer on Active Surveillance — Completed
• Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer — Running, not enrolling
• S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma — Completed
• Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-611) — Completed
• Codex: Study of Inodiftagene Vixteplasmid (BC-819) in Unresponsive NMIBC — Stopped early
• Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms — Completed
• Efficacy and Safety of Multi-Instillations of Apaziquone in Patients With Non-Muscle Invasive Bladder Cancer — Stopped early
• Efficacy Study of ABR-215050 to Treat Prostate Cancer — Completed